

DCAT TOP Industry NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



DCAT

AFTER THE SHOW

A Member Company Networking Event

BARCELONA 2016

WEDNESDAY OCTOBER 5TH • 6:00 PM – 8:30 PM • CASA LLOTJA DE MAR

1. [Bayer, Monsanto Renew Talks for Possible \\$67 Billion Merger](#)

In what would be its first large-scale acquisition as a pure-play life-sciences company, Bayer confirmed that it is in advanced negotiations with the agrochemical and seed company, Monsanto, concerning a proposed transaction in which Bayer would acquire Monsanto for \$67 billion. In July 2016, Bayer upped its original offer to \$62 billion, which it had made in May 2016, to \$65 billion; both times Monsanto rejected the proposal. [Read More](#)

2. [Novartis Disbands Cell And Gene Therapies Unit, Reintegrates Operations](#)

Novartis is disbanding its cell and gene therapies unit and will reintegrate the operations of that unit, including the chimeric antigen receptor (CAR) T-cell technology development, into its main organization. Approximately 120 positions will be affected, but the company said its current work in gene therapy will not be interrupted. [Read More](#)

3. [Allergan Settles Patent-Infringement Litigation For Alzheimer's Drug](#)

Allergan and its subsidiaries, Forest Laboratories, Forest Laboratories Holdings, and Allergan USA, along with Adamas Pharmaceuticals, have settled patent-infringement litigation with Amneal Pharmaceuticals for an abbreviated new drug application for a generic version of Allergan's Namzaric (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination medicine for treating Alzheimer's disease. [Read More](#)

4. [Takeda To Receive \\$312 Million in Zika Funding from US Government](#)

Takeda Pharmaceutical has been selected by the US Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine for the Zika virus. BARDA will supply initial funding of \$19.8 million to cover vaccine development through Phase I with potential funding of up to \$312 million if the vaccine goes through Phase III trials and the filing of a biologics license application in the US. [Read More](#)

5. [Avara Acquires AstraZeneca UK Manufacturing Facility](#)

Avara Pharmaceutical Services, a contract provider of bulk drug formulation, manufacturing, and primary and secondary packaging for solid dose drugs, has agreed to acquire AstraZeneca's manufacturing facility in Avlon, Avonmouth, England. About 210 Avlon employees will remain employed at the site, and the plant will continue to manufacture AstraZeneca pharmaceutical products on a contract basis. This is the second manufacturing facility that Avara has recently acquired. Last month, it agreed to acquire Astellas's wholly owned manufacturing subsidiary, Astellas Pharma Technologies, in Norman, Oklahoma. [Read More](#)

6. [Avantor, Nusil Technology Agree to Merge](#)

Avantor Performance Materials, a specialty and fine chemicals company, including excipients, and NuSil Technology, a silicone-chemistry company, have agreed to merge. Avantor Performance Materials and NuSil are portfolio companies of the equity firm, New Mountain Capital. The combined company will have sales of more than \$700 million. [Read More](#)

7. [Galénica Completes \\$1.53 Billion Acquisition of Relypsa](#)

Galénica Group, a Bern, Switzerland-based specialty pharmaceutical company, has completed its previously announced \$1.53-billion acquisition of the Redwood City, California-based biopharmaceutical company, Relypsa. Galénica's Vifor Pharma Business unit will be combined with Relypsa to create a player in the cardio-renal care market in the US. [Read More](#)

8. [Cambrex To Invest \\$9 Million to Expand API Manufacturing](#)

Cambrex plans to invest SEK 72 million (\$9 million) to expand large-scale manufacturing capacity for active pharmaceutical ingredients (API) at its facility in Karlskoga, Sweden. The expansion is part of an ongoing strategic campaign to invest in small-molecule API manufacturing across the company's global network. In July 2016, the company announced that it had completed and validated a \$50-million production and warehousing expansion for API manufacturing at its cGMP site in Charles City, Iowa. [Read More](#)

9. [AstraZeneca Completes Divestment of Anesthetics Medicines to Aspen](#)

AstraZeneca has completed its previously announced agreement with Aspen Global Incorporated, part of the Aspen Group, for rights to its global anesthetics portfolio outside the US in deal valued up to \$770 million. The closing covers all markets except Ukraine and Zimbabwe, which are subject to separate closing. AstraZeneca first announced the divestment in June 2016. [Read More](#)

10. [Allergan Acquires Gene-Therapy Company](#)

Allergan has acquired RetroSense Therapeutics, an Ann Arbor, Michigan-based clinical-stage biotechnology company focused on gene therapy, for a \$60-million upfront payment and potential regulatory and commercialization milestone payments related to its lead development program, RST-001, a gene therapy for the potential treatment of retinitis pigmentosa. [Read More](#)

****Upcoming DCAT Event****

[DCAT After the Show](#)

Don't miss DCAT's inaugural networking event following CPhI Worldwide in Barcelona on Wednesday, October 5th from 6:00 PM to 8:30 PM at the beautiful Casa Llotja de Mar. Located just steps away from the Gothic Quarter and Port of Barcelona, this event offers the perfect opportunity to utilize that time between the tradeshow and your late-night dinner plans to catch up with colleagues and establish valuable industry connections.

Registration for this event is now open. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org